Figure 4. Clinical analysis of the expression of miR-135a and RAB1B in NSCLC patients. Expression levels of miR-135a and RAB1B were examined in serial dissections of primary tumor and para-carcinoma specimens from 98 NSCLC patients who underwent surgical resections. (A, B) Kaplan-Meier plots of (A) overall survival and (B) relapse-free survival in high- and low-risk groups based on miR-135a expression levels. (C, D) Kaplan-Meier estimates of (C) overall survival and (D) relapse-free survival according to RAB1B expression levels. P-values were obtained from log-rank tests.